Dexamethasone stimulates expression of C-type Natriuretic Peptide in chondrocytes
BMC Musculoskeletal Disorders volume 7, Article number: 87 (2006)
Growth of endochondral bones is regulated through the activity of cartilaginous growth plates. Disruption of the physiological patterns of chondrocyte proliferation and differentiation – such as in endocrine disorders or in many different genetic diseases (e.g. chondrodysplasias) – generally results in dwarfism and skeletal defects. For example, glucocorticoid administration in children inhibits endochondral bone growth, but the molecular targets of these hormones in chondrocytes remain largely unknown. In contrast, recent studies have shown that C-type Natriuretic Peptide (CNP) is an important anabolic regulator of cartilage growth, and loss-of-function mutations in the human CNP receptor gene cause dwarfism. We asked whether glucocorticoids could exert their activities by interfering with the expression of CNP or its downstream signaling components.
Primary mouse chondrocytes in monolayer where incubated with the synthetic glucocorticoid Dexamethasone (DEX) for 12 to 72 hours. Cell numbers were determined by counting, and real-time PCR was performed to examine regulation of genes in the CNP signaling pathway by DEX.
We show that DEX does influence expression of key genes in the CNP pathway. Most importantly, DEX significantly increases RNA expression of the gene encoding CNP itself (Nppc). In addition, DEX stimulates expression of Prkg2 (encoding cGMP-dependent protein kinase II) and Npr3 (natriuretic peptide decoy receptor) genes. Conversely, DEX was found to down-regulate the expression of the gene encoding its receptor, Nr3c1 (glucocorticoid receptor), as well as the Npr2 gene (encoding the CNP receptor).
Our data suggest that the growth-suppressive activities of DEX are not due to blockade of CNP signaling. This study reveals a novel, unanticipated relationship between glucocorticoid and CNP signaling and provides the first evidence that CNP expression in chondrocytes is regulated by endocrine factors.
Bone formation involves the distinct, but related processes of intramembranous ossification and endochondral ossification [1, 2]. While the former forms flatter bones like those of the skull, endochondral ossification is responsible for development of the long bones of the limbs, the vertebrae and the ribs. Endochondral ossification begins when mesenchymal cells condense, differentiate into chondroblasts and then proceed successively through the resting, proliferating, and hypertrophic chondrocyte stages in the cartilage growth plate [2, 3]. The differentiation of mesenchymal cells into chondroblasts is regulated by the activity of the Sox9 transcription factor, which controls the expression of principal genes encoding the extracellular matrix proteins of cartilage, such as collagen type II and aggrecan . Another transcription factor, Runx2, promotes hypertrophic differentiation and stimulates expression of type X collagen, a marker of hypertrophic chondrocytes . The cartilage anlagen serve as the models of future bones, and the rate of proliferation and in particular the volume increase during chondrocyte hypertrophy are the driving forces for bone elongation that determine our final height. Due to the complex nature of cartilage development, it is critical to understand each step involved in regulation of this process, as there are many acquired and inherited cartilage diseases resulting from disturbances in this pathway, including glucocorticoid-induced growth retardation and human chondrodysplasias [6–8]. Recent studies have demonstrated an intricate weave of signaling pathways regulating endochondral ossification, including many hormones and growth factors, such as glucocorticoids and C-type natriuretic peptide (CNP) [6–9].
Long-term administration of anti-inflammatory glucocorticoids (for example in the treatment of childhood asthma, autoimmune diseases or pediatric cancers) results in growth retardation, bone loss, and possible premature or exaggerated osteoporosis . Most glucocorticoid effects on endochondral bone growth appear to be due to direct regulation of chondrocytes, as opposed to generalized endocrine effects [11, 12]. While effects of glucocorticoids on chondrocyte proliferation, differentiation and apoptosis as well as on vascular invasion of hypertrophic cartilage have been reported, the contributions of these effects to growth retardation and the molecular mechanisms involved are not completely understood [7, 8, 13]. Glucocorticoids signal largely through the glucocorticoid receptor (encoded by the Nr3c1 gene), a member of the nuclear receptor family that translocates into the nucleus upon ligand binding and acts as transcription factor , but the molecular targets of glucocorticoids in chondrocytes are largely unknown. Here, we investigated whether expression of genes involved in the CNP signaling pathway is impacted by the administration of a synthetic glucocorticoid, dexamethasone (DEX).
CNP is a member of the natriuretic peptide family consisting of atrial natriuretic peptide (ANP), brain/B-type natriuretic peptide (BNP) and CNP . ANP and BNP act through the same membrane-bound guanylyl cyclase receptor GC-A or NPR1 (gene name in mouse: Npr1), while CNP acts through GC-B/NPR2 (Npr2) to initiate the cGMP-signaling cascade . Elevation in intracellular cGMP levels in response to receptor-ligand interactions results in the activation of downstream mediators such as cyclic nucleotide phosphodiesterases (PDEs), cGMP-regulated ion channels, and cGMP-dependent protein kinases cGKI and cGKII (Prkg1, Prkg2, respectively) [9, 16]. A third type of natriuretic peptide receptor (Npr3) does not posses guanylyl cyclase activity and is thought to act as a decoy/clearance receptor that regulates the levels of natriuretic peptides available for interaction with NPR1 and NPR2 .
Both ANP and BNP are primarily involved in body fluid regulation and cardiovascular function, while a range of functions have been described for CNP, including dilation of smooth muscle cells and regulation of endochondral bone growth [17, 18]. CNP-deficient mice display dwarfism, with significantly reduced lengths of endochondral bones such as femur, tibia, and vertebrae . Histological studies in these mice show decreased growth plate width, resulting from reduced proliferative and hypertrophic zones . A similar phenotype was observed in mice deficient for the CNP receptor Npr2 [20, 21]. Most notably, loss-of-function mutations in the human NPR2 gene cause reduced height and skeletal effects in acromesomelic dysplasia, type Maroteaux [22, 23]. Conversely, CNP treatment results in enhanced endochondral bone growth in organ culture [24, 25]. Moreover, ectopic CNP can rescue the effects of activating mutations in the gene encoding fibroblast growth factor receptor 3 in rodent models of achondroplasia, the most common form of human dwarfism [26, 27]. In summary, there is strong evidence for both an obligatory role of endogenous CNP signaling in normal cartilage development and a potential therapeutic role for exogenous CNP in the treatment of skeletal growth disorders.
CNP is expressed by chondrocytes and appears to control endochondral ossification in an autocrine/paracrine manner , but the mechanisms regulating CNP expression in cartilage are unknown. In this study we asked whether glucocorticoids exert their growth-suppressing effects on bone growth by down-regulation of CNP signaling components.
Cell Culture and Cell Counts
All media components were purchased from Invitrogen, unless stated otherwise. Tibias from CD1 timed-pregnant mice (Charles River Canada) were isolated from 15.5 day embryos under a Stemi DV4 Stereomicroscope (Zeiss). Limb bones were allowed to recover from dissection overnight in serum-free organ culture media containing 0.2% Bovine Serum Albumin (BSA) (Fisher Scientific), 0.5 mM L-glutamine, 40 units penicillin/ml and 40 μg streptomycin/ml. The following day bones were digested with 0.25% trypsin/EDTA for 15 minutes, followed by digestion with 3 mg/mL of Collagenase-P (Roche) in DMEM and 10% FBS for 2 hours at 37°C with constant rotary motion. Cells were plated at a density of 500,000 cells/well in NUNC 6-well plates to adhere overnight in primary cell culture media, consisting of 60% F-12, 40%DMEM, 10% Fetal Bovine Serum (FBS), 0.5 mM L-glutamine, 40 units penicillin/ml and 40 μg streptomycin/ml. Monolayer cultures were treated with DMSO or DEX (10-7M) in DMSO vehicle the following morning. Cells were harvested before treatment and at 12, 24, 48, and 72 hr time points. RNA from primary cells was isolated using QIAGEN (Mississauga) RNeasy® Mini kit and protocol for animal cells.
For cell counts, 100,000 chondrocytes per well were plated into 24-well plates in primary cell culture medium supplemented with DMSO, 10-6 or 10-7 M DEX. After 72 hours, cells were counted using a hematocytometer. Cell counts present average and standard deviation from three independent experiments, performed in triplicate each.
Real-Time PCR analysis for Col2a1 and Col10a1 were performed as described [28–30] using the Applied Biosystems 7900HT Real-Time PCR System and TaqMan® Gene Expression Assays. Nppc, Npr2, Npr3, Nr3c1, Prkg1, Prkg2 and Gapdh probes were purchased as Assays-on-demand (Applied Biosystems) and used the same ways as the Col2a1 and Col10a1 probes. Gene expression levels were determined using the Standard Curve quantitative method with Gapdh levels as the basis of comparison. All data represent averages and SEM from three to four independent cell isolations.
Two-Way ANOVA (parametric) test with Bonferroni post-test was performed using the Graph Pad/Prism software.
We first examined whether DEX would affect the cell number of primary mouse chondrocytes in monolayer culture. In control cultures, cell numbers increased 3.6-fold over a 72 hour time course (Fig. 1A). In contrast, treatment with 10-6 M DEX reduced this increase to 2.4-fold, in agreement with earlier studies [31–33]. 10-7 M DEX caused an even larger reduction, allowing only a doubling of cell numbers. However, the differences between the two DEX concentrations were not statistically significant. Real-time PCR analyses at the same time point demonstrated that 10-7 M DEX does not change the mRNA levels for collagen II significantly (Fig. 1B). DEX treatment appears to increase collagen X mRNA levels slightly, but this increase is not statistically significant (Fig. 1B). These data suggest that DEX treatment did not alter the differentiation status of chondrocytes in these experiments.
We next asked whether DEX would regulate the expression of its own receptor. The expression of the glucocorticoid receptor gene (Nr3c1) was slightly upregulated after 48 and 72 hours in control cultures (Fig 2). However, beginning at the 24 hour time point, DEX significantly down-regulated glucocorticoid receptor mRNA expression. This effect was maintained throughout the time course, reaching maximal inhibition of 38% at 48 hours of DEX treatment.
Since DEX reduces chondrocyte cell numbers and CNP has shown to increase chondrocyte proliferation [19, 24, 25], we asked whether DEX treatment alters the expression of CNP or its receptors. In control conditions, the CNP gene (Nppc) was expressed at constant levels throughout the culture period (Fig. 3A). Surprisingly, DEX caused a significant increase in Nppc mRNA levels, starting at 12 hours and reaching 3.7-fold stimulation after 72 hours of treatment. Expression of the CNP receptor Npr2 increased almost three-fold over the time course under control conditions (Fig. 3B). DEX caused a slight, but significant reduction in Npr2 mRNA levels at 72 hours, with no effects at earlier time points. In control cells, expression of the decoy receptor Npr3 increased more rapidly that that of Npr2, reaching a three-fold increase after 24 hours and dropping slightly after that (Fig. 3C). DEX treatment counteracted this down-regulation and caused increased Npr3 mRNA levels at 48 and 72 hours.
Finally, we examined the effects of DEX treatment on the expression of cGMP-dependent kinases I and II (Prgk1 and Prkg2), two of the main mediators of CNP signaling. Prkg1 gene expression increased slightly during the time course and was not affected by DEX treatment (Fig. 4A). Expression of Prkg2 remained relatively constant throughout the incubation period and was increased slightly, but significantly by DEX treatment (Fig. 4B). Similar to Nppc (but in contrast to the other genes examined), Prkg2 expression responded to DEX at the earliest time point investigated (12 hours).
The process of endochondral ossification involves finely controlled pathways that are not completely understood. These signalling networks likely include crosstalk between different pathways. Here, we have investigated how glucocorticoids impact the expression of various genes in the CNP cascade. It is known that sustained glucocorticoid treatment negatively impacts bone growth in humans, while CNP is a positive regulator of endochondral bone growth. Thus, we speculated that interaction of these two pathways, in particular down-regulation of endogenous CNP signaling by glucocorticoids, could account for some of the effects of these mediators.
We investigated this possibility using primary chondrocytes isolated from 15.5d ay old mouse embryonic forelimbs. Isolated cells were cultured with and without dexamethasone (DEX) for three days. DEX treatment partially inhibited the increase in cell numbers over the incubation period that was seen in control cultures [31–33]. Our data as well as previous studies suggest that this decrease most likely arises from reduced rates of proliferation, but a contribution from increased apoptosis cannot be excluded [31–37]. However, DEX treatment did not result in significant changes in either collagen II or collagen X mRNA expression, indicating that the differentiation status of chondrocytes is not markedly affected by DEX, at least within culture conditions applied here.
Because of the opposing effects of DEX and CNP on chondrocyte cell numbers, we asked whether DEX affects the expression of components of the CNP signalling system, using real-time PCR analyses. The most striking result of our studies was the almost four-fold induction of CNP mRNA expression by DEX. Since CNP and glucocorticoids have opposing effects on endochondral bone growth, these effects were unexpected. Down-regulation of mRNA for the CNP signaling receptor Npr2 and up-regulation of transcript levels for the decoy receptor Npr3 by DEX might counteract increased CNP levels to some degree; however, changes in the mRNA levels for the receptor genes are relatively minor compared to changes in CNP mRNA expression. Furthermore, DEX also increased expression of Prkg2 mRNA, an essential component of CNP signalling in endochondral bone growth . Thus, it is unlikely that glucocorticoid-induced retardation of endochondral bone growth occurs through the blockade of the CNP cascade. Future studies will need to address changes in the protein levels and activities in response to glucocorticoids to assess whether the observed changes in transcripts indeed result in increased CNP signaling. However, recent studies using transgenic mice show that increased CNP mRNA levels directly cause increased CNP signalling [19, 27], suggesting that induction of endogenous CNP mRNA (e.g. in response to DEX) results in increased production of active CNP in a similar manner.
Our data also show that DEX induces modest down-regulation in the expression of its own receptor. These data suggest the existence of a negative feedback response loop limiting glucocorticoid effects, a scenario that is consistent with earlier reports demonstrating that DEX down-regulates expression of the glucocorticoid receptor in other cell types . Nevertheless, cells remained responsive to DEX as demonstrated by our gene expression profiles. In this context, it is of interest that among all examined genes, only Nppc and Prkg2 responded to DEX at the earliest tested time point (12 hours). These data suggest that Nppc could be a direct target of transcriptional regulation by glucocorticoids. However, sequence analyses of the mouse Nppc gene did not identify any apparent glucocorticoid response elements (data not shown). In contrast to Nppc and Prkg2, all other examined genes displayed a slower response to DEX treatment and are likely controlled by glucocorticoids through indirect mechanisms. For example, it has been shown earlier that CNP suppresses the expression of its own receptor, NPR2 . The observed decrease in Npr2 mRNA levels in response to DEX might therefore be secondary to increased CNP levels. Similarly, our recent studies show that increased CNP levels promote the expression of the decoy receptor encoded by Npr3, in another negative feedback loop (Agoston et al., submitted). However, an alternative explanation is that other target genes of glucocorticoids (outside of the CNP signalling system) are responsible for the changes in Npr2 and Npr3 expression.
These studies with primary cells provide the impetus for future exploration into the interactive roles of the glucocorticoid and natriuretic peptide pathways. Despite the opposing roles of the glucocorticoid and CNP signaling pathways in endochondral bone growth, the strong upregulation of CNP mRNA expression by DEX is intriguing, and the elucidation of its role in the cartilage response to glucocorticoids will be of great interest. Furthermore, these studies also demonstrate that the endogenous expression of CNP (and some of the genes mediating CNP signaling) during skeletal development is controlled by endocrine factors.
Our data show that DEX regulates the expression of several components of the CNP signaling pathway. Therefore, our study identifies a novel and potentially important interaction between two pathways that both control endochondral ossification and that both have been implicated in pathologies of endochondral bone growth. Further studies into these pathways and their interactions will contribute to a deeper understanding of endochondral ossification and associated pathologies.
cyclic GMP-dependent kinase
C-type natriuretic peptide
natriuretic peptide receptor
polymerase chain reaction
Karsenty G, Wagner EF: Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002, 2 (4): 389-406. 10.1016/S1534-5807(02)00157-0.
Olsen BR, Reginato AM, Wang W: Bone development. Annu Rev Cell Dev Biol. 2000, 16: 191-220. 10.1146/annurev.cellbio.16.1.191.
Stanton LA, Underhill TM, Beier F: MAP kinases in chondrocyte differentiation. Dev Biol. 2003, 263 (2): 165-175. 10.1016/S0012-1606(03)00321-X.
Lefebvre V, de Crombrugghe B: Toward understanding SOX9 function in chondrocyte differentiation. Matrix Biol. 1998, 16 (9): 529-540. 10.1016/S0945-053X(98)90065-8.
Zheng Q, Zhou G, Morello R, Chen Y, Garcia-Rojas X, Lee B: Type X collagen gene regulation by Runx2 contributes directly to its hypertrophic chondrocyte-specific expression in vivo. J Cell Biol. 2003, 162 (5): 833-842. 10.1083/jcb.200211089.
Ballock RT, O'Keefe RJ: Physiology and pathophysiology of the growth plate. Birth Defects Res Part C Embryo Today. 2003, 69 (2): 123-143. 10.1002/bdrc.10014.
Robson H, Siebler T, Shalet SM, Williams GR: Interactions between GH, IGF-I, glucocorticoids, and thyroid hormones during skeletal growth. Pediatr Res. 2002, 52 (2): 137-147. 10.1203/01.PDR.0000023494.70201.1C.
van der Eerden BCJ, Karperien M, Wit JM: Systemic and Local Regulation of the Growth Plate. Endocr Rev. 2003, 24 (6): 782-801. 10.1210/er.2002-0033.
Komatsu Y, Chusho H, Tamura N, Yasoda A, Miyazawa T, Suda M, Miura M, Ogawa Y, Nakao K: Significance of C-type natriuretic peptide (CNP) in endochondral ossification: analysis of CNP knockout mice. J Bone Miner Metab. 2002, 20 (6): 331-336. 10.1007/s007740200048.
Avioli LV: Glucocorticoid effects on statural growth. Br J Rheumatol. 1993, 32 (Suppl 2): 27-30.
Baron J, Klein KO, Colli MJ, Yanovski JA, Novosad JA, Bacher JD, Cutler GB: Catch-up growth after glucocorticoid excess: a mechanism intrinsic to the growth plate. Endocrinology. 1994, 135 (4): 1367-1371. 10.1210/en.135.4.1367.
Baron J, Huang Z, Oerter KE, Bacher JD, Cutler GB: Dexamethasone acts locally to inhibit longitudinal bone growth in rabbits. Am J Physiol. 1992, 263 (3 Pt 1): E489-492.
Canalis E, Pereira RC, Delany AM: Effects of glucocorticoids on the skeleton. J Pediatr Endocrinol Metab. 2002, 15 (Suppl 5): 1341-1345.
Yudt MR, Cidlowski JA: The Glucocorticoid Receptor: Coding a Diversity of Proteins and Responses through a Single Gene. Mol Endocrinol. 2002, 16 (8): 1719-1726. 10.1210/me.2002-0106.
Baxter GF: The natriuretic peptidesAn introduction. Basic Res Cardiol. 2004, 99 (2): 71-75. 10.1007/s00395-004-0457-8.
Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA: Guanylyl Cyclases and Signaling by Cyclic GMP. Pharmacol Rev. 2000, 52 (3): 375-414.
Schulz S: C-type natriuretic peptide and guanylyl cyclase B receptor. Peptides. 2005, 26 (6): 1024-1034. 10.1016/j.peptides.2004.08.027.
Kuhn M: Molecular physiology of natriuretic peptide signalling. Basic Res Cardiol. 2004, 99 (2): 76-82. 10.1007/s00395-004-0460-0.
Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, Nakamura K, Nakao K, Kurihara T, Komatsu Y: Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci USA. 2001, 98: 4016-4021. 10.1073/pnas.071389098.
Tsuji T, Kunieda T: A Loss-of-Function Mutation in Natriuretic Peptide Receptor 2 (Npr2) Gene Is Responsible for Disproportionate Dwarfism in cn/cn Mouse. J Biol Chem. 2005, 280 (14): 14288-14292. 10.1074/jbc.C500024200.
Tamura N, Doolittle LK, Hammer RE, Shelton JM, Richardson JA, Garbers DL: Critical roles of the guanylyl cyclase B receptor in endochondral ossification and development of female reproductive organs. PNAS. 2004, 101 (49): 17300-17305. 10.1073/pnas.0407894101.
Bartels CF, Bukulmez H, Padayatti P, Rhee DK, van Ravenswaaij-Arts C, Pauli RM, Mundlos S, Chitayat D, Shih LY, Al-Gazali LI: Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet. 2004, 75 (1): 27-34. 10.1086/422013.
Olney RC: C-type natriuretic peptide in growth: A new paradigm. Growth Horm IGF Res. 2006, 16S: 6-14. 10.1016/j.ghir.2006.03.016.
Mericq V, Uyeda JA, Barnes KM, De Luca F, Baron J: Regulation of fetal rat bone growth by C-type natriuretic peptide and cGMP. Pediatr Res. 2000, 47 (2): 189-193.
Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, Chusho H, Shiota K, Tanaka K, Nakao K: Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem. 1998, 273 (19): 11695-11700. 10.1074/jbc.273.19.11695.
Krejci P, Masri B, Fontaine V, Mekikian PB, Weis M, Prats H, Wilcox WR: Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci. 2005, 118 (21): 5089-5100. 10.1242/jcs.02618.
Yasoda A, Komatsu Y, Chusho H, Miyazawa T, Ozasa A, Miura M, Kurihara T, Rogi T, Tanaka S, Suda M: Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway. Nat Med. 2004, 10 (1): 80-86. 10.1038/nm971.
Woods A, Wang G, Beier F: RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis. J Biol Chem. 2005, 280 (12): 11626-11634. 10.1074/jbc.M409158200.
Stanton LA, Sabari S, Sampaio AV, Underhill TM, Beier F: p38 MAP kinase signalling is required for hypertrophic chondrocyte differentiation. Biochem J. 2004, 378 (Pt 1): 53-62. 10.1042/BJ20030874.
James CG, Appleton CTG, Ulici V, Underhill TM, Beier F: Microarray Analyses of Gene Expression during Chondrocyte Differentiation Identifies Novel Regulators of Hypertrophy. Mol Biol Cell. 2005, 16 (11): 5316-5333. 10.1091/mbc.E05-01-0084.
Klaus G, Jux C, Fernandez P, Rodriguez J, Himmele R, Mehls O: Suppression of growth plate chondrocyte proliferation by corticosteroids. Pediatr Nephrol. 2000, 14 (7): 612-615. 10.1007/s004670000344.
Smink JJ, Koedam JA, Koster JG, van Buul-Offers SC: Dexamethasone-induced growth inhibition of porcine growth plate chondrocytes is accompanied by changes in levels of IGF axis components. J Endocrinol. 2002, 174 (2): 343-352. 10.1677/joe.0.1740343.
Hainque B, Dominice J, Jaffray P, Ronot X, Adolphe M: Effects of dexamethasone on the growth of cultured rabbit articular chondrocytes:relation with the nuclear glucocorticoid-receptor complex. Ann Rheum Dis. 1987, 46 (2): 146-152.
Silvestrini G, Ballanti P, Patacchioli FR, Mocetti P, Di Grezia R, Wedard BM, Angelucci L, Bonucci E: Evaluation of apoptosis and the glucocorticoid receptor in the cartilage growth plate and metaphyseal bone cells of rats after high-dose treatment with corticosterone. Bone. 2000, 26 (1): 33-42. 10.1016/S8756-3282(99)00245-8.
Chrysis D, Ritzen EM, Savendahl L: Growth retardation induced by dexamethasone is associated with increased apoptosis of the growth plate chondrocytes. J Endocrinol. 2003, 176 (3): 331-337. 10.1677/joe.0.1760331.
Chrysis D, Zaman F, Chagin AS, Takigawa M, Savendahl L: Dexamethasone Induces Apoptosis in Proliferative Chondrocytes through Activation of Caspases and Suppression of the Akt-Phosphatidylinositol 3'-Kinase Signaling Pathway. Endocrinology. 2005, 146 (3): 1391-1397. 10.1210/en.2004-1152.
Nakazawa F, Matsuno H, Yudoh K, Watanabe Y, Katayama R, Kimura T: Corticosteroid treatment induces chondrocyte apoptosis in an experimental arthritis model and in chondrocyte cultures. Clin Exp Rheumatol. 2002, 20 (6): 773-781.
Miyazawa T, Ogawa Y, Chusho H, Yasoda A, Tamura N, Komatsu Y, Pfeifer A, Hofmann F, Nakao K: Cyclic GMP-dependent protein kinase II plays a critical role in C-type natriuretic peptide-mediated endochondral ossification. Endocrinology. 2002, 143 (9): 3604-3610. 10.1210/en.2002-220307.
Oakley RH, Cidlowski JA: Homologous down regulation of the glucocorticoid receptor: the molecular machinery. Crit Rev Eukaryot Gene Expr. 1993, 3 (2): 63-88.
Rahmutula D, Gardner DG: C-Type Natriuretic Peptide Down-Regulates Expression of Its Cognate Receptor in Rat Aortic Smooth Muscle Cells. Endocrinology. 2005, 146 (11): 4968-4974. 10.1210/en.2005-0262.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/7/87/prepub
H.A. was supported by an Ontario Graduate Scholarship, and L.B. was the recipient of summer studentships from NORTH. Work in the lab of F.B. is supported by a Canada Research Chair Award, a Premier's Research Excellence Award from the Province of Ontario, and funds from the Canadian Institutes of Health Research, The Arthritis Society, the National Science and Engineering Research Council, the Canadian Arthritis Network and the Sick Kids Foundation.
The author(s) declare that they have no competing interests.
HA performed the real-time PCR analyses, co-wrote the manuscript and contributed to the design of the study. LB carried out the proliferation studies. FB conceived and designed the study and co-wrote the manuscript. All authors read and approved the final manuscript.
About this article
Cite this article
Agoston, H., Baybayan, L. & Beier, F. Dexamethasone stimulates expression of C-type Natriuretic Peptide in chondrocytes. BMC Musculoskelet Disord 7, 87 (2006). https://doi.org/10.1186/1471-2474-7-87